aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 341,600 shares, a growth of 5.4% from the August 15th total of 324,000 shares. Based on an average daily trading volume, of 131,700 shares, the days-to-cover ratio is presently 2.6 days.

aTyr Pharma Stock Down 3.9 %

aTyr Pharma stock opened at $2.93 on Wednesday. The firm's fifty day moving average price is $3.49 and its two-hundred day moving average price is $3.76. aTyr Pharma has a 1-year low of $2.60 and a 1-year high of $13.10.

aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its quarterly earnings results on Monday, August 15th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). During the same quarter last year, the company earned ($0.64) EPS. Analysts anticipate that aTyr Pharma will post -1.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

Hedge Funds Weigh In On aTyr Pharma

Several large investors have recently bought and sold shares of LIFE. Tikvah Management LLC bought a new stake in shares of aTyr Pharma in the 4th quarter worth $9,157,000. Deep Track Capital LP purchased a new stake in aTyr Pharma in the 4th quarter valued at about $8,217,000. Stonepine Capital Management LLC lifted its position in shares of aTyr Pharma by 28.0% during the 4th quarter. Stonepine Capital Management LLC now owns 525,531 shares of the biotechnology company's stock worth $3,926,000 after buying an additional 114,996 shares in the last quarter. Alyeska Investment Group L.P. boosted its stake in shares of aTyr Pharma by 12.7% in the 1st quarter. Alyeska Investment Group L.P. now owns 760,798 shares of the biotechnology company's stock worth $4,070,000 after buying an additional 85,823 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of aTyr Pharma in the fourth quarter valued at approximately $439,000. 65.58% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on LIFE. Piper Sandler raised their price target on shares of aTyr Pharma from $11.00 to $14.00 and gave the stock an "overweight" rating in a report on Monday, August 15th. StockNews.com lowered aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Wednesday, September 14th. Finally, HC Wainwright increased their price target on aTyr Pharma from $11.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, July 21st.

About aTyr Pharma

(Get Rating)

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

Recommended Stories

• Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
• 3 Defensive Stocks With 60-Year Dividend Hike Streaks
• 3 Airline Stocks Stuck in a Holding Pattern
• Roku Stock is Down but Not Out
• If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
• Is Ford Rolling To A Rebound After Its Q3 Warning

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.